Navigation Links
Kidney advocates launch $10.25 million effort to examine cause of kidney failure
Date:9/22/2009

University of Michigan Health System researchers will lead a $10.25 million effort to study rare kidney diseases that cause kidney failure and the need for dialysis.

The five-year project supports research of nephrotic syndrome, which describes a group of diseases that, though rare, generates an enormous individual and societal burden. The syndrome, which affects kidney filter cells, contributes to nearly 12 percent of cases of kidney failure, and an annual cost of more than $3 billion.

The Nephrotic Syndrome Rare Disease Consortium will bring together a network of investigators from the United States and Canada, and two highly active patient interest groups, the Nephcure Foundation and the Halpin Foundation, to create a network for collecting patient information, facilitating clinical and observational studies and training future researchers.

The National Institutes of Health Office of Rare Diseases, the National Institutes of Diabetes, Digestive and Kidney Disease awarded a $6.25 million grant to the U-M, with NephCure committing $2 million and U-M contributing a total of $2 million.

NephCure, a Pennsylvania-based patient advocacy and research funding organization, will continue to have a role in recruiting and educating patients. NephCure has contributed more than $6 million to research over the past several years.

"The kidney community has had a strong interest in this work for a long time, but, until now, we have not had adequate funding for a coordinated effort," says project director Matthias Kretzler, M.D., professor of internal medicine at the U-M Medical School and a nephrologist at the U-M Health system.

"This has the potential to change the way we understand and treat patients with nephrotic syndrome," he says. "NephCure's support was critically important in winning this award and will be vital to our long term success."

Kretzler, along with U-M medical school researchers Akinlolu Ojo, M.D., Ph.D., professor in internal medicine, and Lawrence B. Holzman, M.D., professor of internal medicine, will provide the leadership for the multi-center consortium.

"As a premier research institution, we're well-positioned to take advantage of a rapidly expanding knowledge of genetics and the power of bioinformatics to transform our understanding and treatment of rare diseases," says James Shayman, M.D., associate vice president for research at the University of Michigan.

"We recognize that combining our own institutional resources with those of the NIH and NephCure Foundation creates a unique opportunity for promoting rare disease research in nephrotic syndrome," he says.

A seed grant from the university's Office of the Vice President for Research Rare Disease Initiative was instrumental in securing funding for the new consortium.

While the U-M will function as the central operational hub, clinical investigators from 11 academic medical centers will make up the research team.

One of the joint initiatives will be to establish and maintain a Web site with educational and networking resources for patients, families, physicians and scientists.

Researchers will investigate minimal change disease, focal and segmental glomerulosclerosis, and membranous nephropathy, diseases known to damage kidney filter cells and can lead to kidney failure and death.

Some types of the syndrome are hereditary, but it can also manifest later in life for reasons largely unknown. The network will use molecular medicine tools to unravel the mechanism responsible for the diseases and potentially develop new targeted treatment therapies.


'/>"/>

Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Diet, Exercise May Slow Kidney Disease Progression
2. Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age
3. Extended Antiviral May Benefit Kidney Transplant Patients
4. Satellite Healthcare Helps Support the Cure for Kidney Disease in Sacramento
5. September 2009 Mayo Clinic Health Letter Highlights Snoring, Kidney Stones and Vitamin D
6. Kidney Injury While Hospitalized May Lead to Future Dialysis
7. New Data Shows DaVita Facilities Lead Virginia in Improving Kidney Patient Care
8. DaVita Launches Nationwide Series of Kidney Awareness Run/Walks
9. Success of National Fundraising Event Critical to Promising Research for Life-Threatening Kidney Disease
10. DaVitas Patient-Centric Modalities Offer Students with Kidney Disease More Choices
11. Texas Kidney Community Expresses Hope DC Health Care Reform Debate Can Help Drive Continued Progress in Texas Opening Needed Dialysis Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology: